Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from Brokerages

Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have been given a consensus recommendation of "Buy" by the seven analysts that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $12.14.

Several research firms have issued reports on RZLT. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. Wedbush reaffirmed an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a report on Wednesday, May 14th. JMP Securities lifted their price target on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a report on Thursday, February 13th. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Rezolute in a report on Monday, April 28th.

Insider Transactions at Rezolute

In related news, CFO Daron Evans bought 10,000 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the acquisition, the chief financial officer now owns 237,900 shares in the company, valued at $687,531. This trade represents a 4.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nevan C. Elam bought 12,302 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was bought at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. This trade represents a 5.81% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 29,060 shares of company stock worth $83,694. Company insiders own 18.39% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in shares of Rezolute during the third quarter worth about $42,000. Charles Schwab Investment Management Inc. grew its position in Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after buying an additional 9,000 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Rezolute by 62.1% during the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after purchasing an additional 24,742 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Rezolute by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after purchasing an additional 25,413 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in shares of Rezolute during the 4th quarter valued at about $277,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Stock Up 6.4%

Shares of RZLT stock opened at $3.80 on Tuesday. The stock has a market cap of $230.03 million, a P/E ratio of -3.11 and a beta of 1.01. Rezolute has a 52 week low of $2.22 and a 52 week high of $6.19. The company's fifty day simple moving average is $3.24 and its two-hundred day simple moving average is $4.28.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). On average, analysts anticipate that Rezolute will post -0.93 EPS for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.